Amitabh Gaur, Ph.D. Email & Phone Number

Greater San Diego Area

Providing consulting and scientific advice in the area of design and development of a) biological therapeutics b) cell based therapies including Immunotherapies like CAR-T cells c) vaccines to emerging diseases e.g., dengue, chikungunya d) novel immuno assays for various indications like transplantation, infectious diseases, autoimmunity, cancer etc., based upon antigen and antibody detection on various platforms including flow cytometry e) novel platforms including… Show more Providing consulting and scientific advice in the area of design and development of a) biological therapeutics b) cell based therapies including Immunotherapies like CAR-T cells c) vaccines to emerging diseases e.g., dengue, chikungunya d) novel immuno assays for various indications like transplantation, infectious diseases, autoimmunity, cancer etc., based upon antigen and antibody detection on various platforms including flow cytometry e) novel platforms including instruments and assays SIMPLEXITY PRODUCT DEVELOPMENT, San Diego: Senior Science Advisor --- assisting in the development of novel diagnostic platforms.INNOVATIVE ASSAY SOLUTIONS: Consulting with Pharma and biotech developing effective, customized assays for biomedical research and clinical applications.Currently available to apply my diverse skill-set to consulting, and full or part-time roles. I can be reached at agaursd@gmail.comPRIOR CONSULTING EXPERIENCEInvited by CIRM(California Institute for Regenerative Medicine) to discuss with FDA development of safety guidelines for cell therapyAdvised Venture Capital company on merit of proposed businessesConsulted with government on feasibility of developing effective assays to identify biologic threats Show less

San Diego, California, United States

Washington D.C. Metro Area

Greater San Diego Area

Consultant for a Vaccine development company establishing a GCP (Good Clinical Practices ) laboratory. Successfully established the lab to carry out clinical assays and enabled delivery of results on thousands of samples from over 400 subjects in a Phase II clinical trial of a candidate vaccine for Chikungunya virus.

San Diego

Greater San Diego Area

Director, Custom Technology Business Unit (CTT)Recruited to be the Business and Scientific leader of the new Custom Technology Business developing novel assay solutions for a broad range of Biomedical Applications. Budget & P&L responsibilities.Member, Business Leadership Team with overall responsibility of managing and growing the San Diego site –(320 employees).• Grew the CTT Business by double digits year over year achieving budgeted yearly top line revenue targets while… Show more Director, Custom Technology Business Unit (CTT)Recruited to be the Business and Scientific leader of the new Custom Technology Business developing novel assay solutions for a broad range of Biomedical Applications. Budget & P&L responsibilities.Member, Business Leadership Team with overall responsibility of managing and growing the San Diego site –(320 employees).• Grew the CTT Business by double digits year over year achieving budgeted yearly top line revenue targets while delivering high profit margins.• Expanded the range of Assay Solutions broadening the custom product portfolio into the following fields – Leukemia and Lymphoma diagnosis; Vaccine efficacy monitoring, Autoimmune therapeutics, Cell Therapy, Biological therapeutics- Immunogenicity.• Successfully promoted the CTT Business globally – Europe, Japan, Australia, Canada, Latin America.• Established the complete infrastructure and processes at BD to carry out assays for clinical trials including assay development, assay validation, sample tracking and receipt systems to receive samples from clinical trials from global sites. Customers included most of the major Pharmaceutical and Biotechnology companies worldwide.• Established robust Quality Systems that passed audits carried out by drug companies and Quality organizations including ISO.• Leader in innovation in the company – brought new technologies and reduced them to practical applications turning them into revenue growth drivers and making BD the leader in the field.• Managed CTT as a separate Manufacturing Plant within the BD Biosciences Operations improving operational efficiency in an SAP environment. Show less

Greater San Diego Area

A Biotech founded in 1994 with the aim of developing novel therapeutics for neurological and autoimmune disorders based upon pioneering research carried out at the Salk Institute and Stanford University.Joined the effort as one of the first immunologists at the start-up Biotech to lead the program on development of novel therapeutics for autoimmune disorders – Type I Diabetes and Multiple SclerosisProject Leader: Autoimmune Diabetes ProgramConceived and established a research… Show more A Biotech founded in 1994 with the aim of developing novel therapeutics for neurological and autoimmune disorders based upon pioneering research carried out at the Salk Institute and Stanford University.Joined the effort as one of the first immunologists at the start-up Biotech to lead the program on development of novel therapeutics for autoimmune disorders – Type I Diabetes and Multiple SclerosisProject Leader: Autoimmune Diabetes ProgramConceived and established a research program to develop therapeutics for Type I Diabetes. Successfully managed the project leading to selection of a drug candidate for filing of an IND or CTX (British equivalent to FDA IND). • Established in-house animal model for diabetes and directed and conducted immunological and pharmacological research leading to selection of drug candidate.• Managed and conducted ex vivo studies on biological samples from diabetic patients.• Investigated and established the mechanisms of action of the Altered Peptide Ligands (APL) employing in vitro and in vivo methods of analysis.• Established methods and strategies for developing surrogate markers for evaluation of the efficacy of the drug in clinical trials.Multiple Sclerosis (MS) ProgramEstablished a research program for development of a peptide based therapeutic for Multiple Sclerosis.• Developed the appropriate APL for evaluation in clinical trials - in the process firmly establishing the APL technology platform for the Company• Established an acute model for MS in the rats and a chronic relapsing model for MS in the mouse. Used both models for evaluation and selection of the drug candidate which completed Phase I clinical trial and went on to Phase II/III trials• Basic research in the animal models also led to a partnering agreement with CIBA/Novartis.• Prepared supporting documents for filing the IND application Show less

Greater San Diego Area

• Scientific Advisory Board meetings for the NIH-NIAID Sponsored EQAPOL Program on behalf of the BD –Duke University alliance – 2013-2016 at Duke University• Member – Faculty of the Immunology Course in India supported by the Cancer Institute in New York, 2008 - Kochi, India• Invited to attend the Indo – US Symposium on Genetic Disorders, Varanasi, India, October 2006• Member – Faculty of the Immunology Course in India supported by the Cancer Institute in New York… Show more • Scientific Advisory Board meetings for the NIH-NIAID Sponsored EQAPOL Program on behalf of the BD –Duke University alliance – 2013-2016 at Duke University• Member – Faculty of the Immunology Course in India supported by the Cancer Institute in New York, 2008 - Kochi, India• Invited to attend the Indo – US Symposium on Genetic Disorders, Varanasi, India, October 2006• Member – Faculty of the Immunology Course in India supported by the Cancer Institute in New York, 2006• Co-Chairman of the symposium on Regulatory T Cells in Disease States at the XII International Congress of Immunology/FOCIS Conference, Montreal, Canada, July, 2004• Co-Chairman of the symposium on Flow Cytometry Present and Future at the FOCIS (Federation of Clinical Immunology Societies Meeting) 3rd Annual Conference, Paris, France, 2003• Co-Chairman of the symposium at the FOCIS (Federation of Clinical Immunology Societies Meeting) 2nd Annual Conference, San Francisco, 2002• Chairperson/invited speaker at the IBC’s Annual Conference on Multiple Sclerosis, Washington, Dec 1998• Invited speaker at the National Multiple Sclerosis Society sponsored Multiple Sclerosis Scientific and Medical Symposium, Boston, 1997• Invited speaker at the 1997 FASEB Summer Conference on Autoimmunity, Saxtons River, Vermont 1997• Invited speaker at the IBC's 4th International Conference on Advances in the Understanding and Treatment of Multiple Sclerosis, San Francisco, 1996• Invited speaker at the Cambridge Healthtech Institute's Conference on Prevention and Treatment of Multiple Sclerosis, Atlanta, 1996• Invited speaker at the IBC's 3rd International Conference on Advances in the Understanding and Treatment of Multiple Sclerosis, Cambridge, 1995• Invited speaker at the International Conference of American Lung Association and American Thoracic Society, San Francisco, 1993• Rockefeller Foundation Award on the paper presented- 3rd International Congress of Reproductive Immunology, Toronto, and 1986 Show less

New Delhi Area, India

Major new institution, the first of its kind in India, focused on the development of vaccines.Designed and directed the preparation of a new vaccine for controlling fertility under GMP conditions for use in Phase I clinical trials.Developed novel strategies for overcoming epitope specific immune suppression in hapten-carrier conjugated candidate vaccines.

Post Doctoral Fellow, Immunology / Autoimmunity / Medicine

Activities and Societies: Post Doctoral Fellow Stanford University Medical Center, Department of Medicine Life Sciences Research.

Ph.D., Biochemistry/Immunology